Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents

Journal of Medicinal Chemistry

Volumn 46, Issue 13, 2003, Pages 2716-2730

  Kuehne, Martin E ^a   He, Liwen ^a   Jokiel, Patrick A ^a   Pace, C J ^b   Fleck, M W ^b   Maisonneuve, I M ^b   Glick, Stanley D ^b   Bidlack, Jean M ^c  

^a UNIVERSITY OF VERMONT   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

18 METHOXYCORONARIDINE; ALPHA 3 BETA 4 NICOTINIC RECEPTOR; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT;

ANIMALS; CELL LINE; HUMANS; IBOGAINE; MORPHINE DEPENDENCE; PATCH-CLAMP TECHNIQUES; RATS; RECEPTORS, NICOTINIC; RECEPTORS, OPIOID; SELF ADMINISTRATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTANCE-RELATED DISORDERS;

EID: 0038792268     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020562o     Document Type: Article

References (29)

1. Glick, S. D.; Maisonneuve, I. M. Development of novel medications for drug addiction. The legacy of an African shrub. Ann. N. Y. Acad. Sci. 2000, 909, 88-103.
2. (a) Popik, P.; Layer, R. T.; Skolnick, P. 100 years of ibogaine: Neurochemical and pharmacological actions of a putative antiaddictive drug. Pharmacol. Rev. 1995, 47, 235.
3. (b) Popik, P.; Skolnick, P. Pharmacology of ibogaine and ibogaine related alkaloids. In The Alkaloids; Cordell, G. A., Ed.; Academic Press: San Diego, 1998; Vol. 53, pp 197-231.
4. (c) Ibogaine: Proceedings of the First International Conference. The Alkaloids; Alper, K. R., Glick, S. D., Eds.; Academic Press: San Diego, 2001; Vol. 56, pp 1-333.
5. (d) Lotsof, H. S. Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent 4,499,096, 1985. Lotsof, H. S. Rapid method for interrupting the cocaine and methamphetamine abuse syndrome. U.S. Patent 4,587,243, 1986. Lotsof, H. S. Treatment of alcohol dependence with ibogaine. US patent 4,857,523, 1989. Rapid method of interrupting or attenuating the nicotine/tobacco dependency syndrome. U.S. Patent 5,026,697, 1991. Lotsof, H. S. A rapid method for interrupting or attenuating poly-drug dependency syndromes. U.S. Patent 5,152,994, 1992.
6. (d) Lotsof, H. S. Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent 4,499,096, 1985. Lotsof, H. S. Rapid method for interrupting the cocaine and methamphetamine abuse syndrome. U.S. Patent 4,587,243, 1986. Lotsof, H. S. Treatment of alcohol dependence with ibogaine. US patent 4,857,523, 1989. Rapid method of interrupting or attenuating the nicotine/tobacco dependency syndrome. U.S. Patent 5,026,697, 1991. Lotsof, H. S. A rapid method for interrupting or attenuating poly-drug dependency syndromes. U.S. Patent 5,152,994, 1992.
7. (d) Lotsof, H. S. Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent 4,499,096, 1985. Lotsof, H. S. Rapid method for interrupting the cocaine and methamphetamine abuse syndrome. U.S. Patent 4,587,243, 1986. Lotsof, H. S. Treatment of alcohol dependence with ibogaine. US patent 4,857,523, 1989. Rapid method of interrupting or attenuating the nicotine/tobacco dependency syndrome. U.S. Patent 5,026,697, 1991. Lotsof, H. S. A rapid method for interrupting or attenuating poly-drug dependency syndromes. U.S. Patent 5,152,994, 1992.
8. (d) Lotsof, H. S. Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent 4,499,096, 1985. Lotsof, H. S. Rapid method for interrupting the cocaine and methamphetamine abuse syndrome. U.S. Patent 4,587,243, 1986. Lotsof, H. S. Treatment of alcohol dependence with ibogaine. US patent 4,857,523, 1989. Rapid method of interrupting or attenuating the nicotine/tobacco dependency syndrome. U.S. Patent 5,026,697, 1991. Lotsof, H. S. A rapid method for interrupting or attenuating poly-drug dependency syndromes. U.S. Patent 5,152,994, 1992.
9. (d) Lotsof, H. S. Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent 4,499,096, 1985. Lotsof, H. S. Rapid method for interrupting the cocaine and methamphetamine abuse syndrome. U.S. Patent 4,587,243, 1986. Lotsof, H. S. Treatment of alcohol dependence with ibogaine. US patent 4,857,523, 1989. Rapid method of interrupting or attenuating the nicotine/tobacco dependency syndrome. U.S. Patent 5,026,697, 1991. Lotsof, H. S. A rapid method for interrupting or attenuating poly-drug dependency syndromes. U.S. Patent 5,152,994, 1992.
10. Singbartl, G.; Zetler, G.; Schlosser, L. Structure-activity relationships of intracerebrally injected tremorigenic alkaloids. Neuropharmacology 1973, 12, 239-244.
11. Glick, S. D.; Kuehne, M. E.; Raucci, J.; Wilson, T. E.; Larson, T. D.; Keller, R. W.; Carlson, J. N. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 1994, 657, 14-22.
12. (a) Bandarage, U. K.; Kuehne, M. E.; Glick, S. D. Total syntheses of albifloranine and its anti-addictive congeners, including 18-methoxycoronaridine. Tetrahedron 1999, 55, 9405-9425.
13. (b) Kuehne, M. E.; Wilson, T. E.; Bandarage, U. K.; Dai, W.; Yu, Q. Enantioselective syntheses of coronaridine and 18-methoxycoronaridine. Tetrahedron 2001, 57, 2085-2094.
14. (a) Glick, S. D.; Maisonneuve, I. M.; Szumlinski, K. K. 18- Methoxycoronaridine (18-MC) and ibogaine: Comparison of anti-addictive efficacy, toxicity, and mechanism of action. Ann. N. Y. Acad. Sci. 2000, 914, 369-386.
15. (b) Bandarage, U. K.; Kuehne, M. E.; Glick, S. D. Chemical synthesis and biological evaluation of 18-methoxycoronaridine (18-MC) as a potential anti-addictive agent. Curr. Med. Chem.: Cent. Nerv. Syst. Agents 2001, 1, 113-123.
16. (a) Glick, S. D.; Kuehne, M. E.; Maisonneuve, I. M.; Bandarage, U. K.; Molinari, H. H. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects on morphine and cocaine selfadministration and on mesolimbic dopamine release in rats. Brain Res. 1996, 719, 29-35.
17. (b) Glick, S. D.; Maisonneuve, I. M.; Hough, L. H.; Kuehne, M. E.; Bandarage, U. K. (±)-18- Methoxycoronaridine: A novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Rev. 1999, 5, 27-42.
18. Maisonneuve, I. M.; Glick, S. D. Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. Eur. J. Pharmacol. 1999, 383, 15.
19. Rezvani, A. H.; Overstreet, D. H.; Yang, Y.; Maisonneuve, I. M.; Bandarage, U. K.; Kuehne, M. E.; Glick, S. D. Attenuation of alcohol consumption by a novel non-toxic ibogaine analog (18- methoxycoronaridine) in alcohol preferring rats. Pharmacol. Biochem. Behav. 1997, 58, 615-619.
20. Glick, S. D.; Maisonneuve, I. M.; Dickinson, H. A. 18-MC reduces methamphetamine and nicotine self-administration in rats. NeuroReport 2000, 11, 2013-2015.
21. Zhang, W.; Tyndale, R. F.; Glick, S. D.; Maisonneuve, I. M.; Kuehne, M. E.; Sellers, E. M. Metabolism of 18-methoxycoronaridine, an ibogamine analog, to 18-hydroxycoronaridine by genetically variable CYPZC 19. Drug Metab. Dispos. 2002, 30, 663-669.
22. Glick, S. D.; Maisonneuve, I. M.; Kitchen, B. A.; Fleck, M. W. Antagonism of α3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur. J. Pharmacol. 2002, 438, 99-105.
23. Papke, R. L.; Sanberg, P. L.; Shytle, R. D. Ananlysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 2001, 297, 646-656.
24. Hernandez, S. C.; Bertolino, M.; Xiao, Y.; Pringle, K. E.; Caruso, F. S.; Kellar, K. J. Dextromorphan and its metabolite dextrophan block α3β4 neuronal nicotinic receptors. J. Pharmacol. Exp. Ther. 2000, 293, 962-967.
25. Chan, T. H.; Brook, M. A.; Chaly, T. A simple procedure for acetalization of carbonyl compounds. Synthesis 1983, 203-205.
26. Kuehne, M. E.; Bohnert, J. C.; Bornmann, W. G.; Kirkemo, C. L.; Kuehne, S. E.; Seaton, P. J.; Zebovitz, T. C. Biomimetic syntheses of indole alkaloids. 11. Syntheses of β-carboline and indoloazepine intermediates. J. Org. Chem. 1985, 50, 919.
27. Bornmann, W. G.; Kuehne, M. E. A common intermediate providing syntheses of ψ-tabersonine, coronaridine, iboxyphylline, vinamidine, and vinblastine. J. Org. Chem. 1992, 57, 1752.
28. 3H]U69,593, respectively.
29. 9